Invivyd Stock Earnings Reports

Invivyd reported progress across clinical, commercial and R&D fronts in Q1 2026. Key clinical updates: the pivotal DECLARATION study for VYD2311 is near completion after an earlier upsizing; the IDMC recommended reducing post-dose monitoring from 2 hours to 30 minutes (interpreted as a positive safety signal); the LIBERTY study (evaluating combination of vaccine + monoclonal antibody and direct tolerability comparisons) is expected to open soon. Scientific updates: Invivyd confirmed neutralization activity of its candidates against Omicron BA.3.2 and continues to expand its early-discovery pipeline into other vaccine-preventable and high-burden pathogens (measles, RSV, mumps, rubella, Lyme). Commercial/financial: monoclonal antibody revenues are growing (PEMGARDA up 22% YoY in 1Q), vaccine revenue declined; the company raised additional cash in April and increased near-term clinical spend to support DECLARATION, with the expectation of normalized R&D spend as the pivotal completes. Commercial strategy highlights include leveraging existing PEMGARDA infrastructure for VYD2311, greater use of AI for HCP outreach, and expanded DTC efforts. Management emphasized government affairs outreach and public education about antibodies, and reiterated confidence in VYD2311’s safety/tolerability and anticipated strong efficacy (company dosed with expectation of high antiviral titers). Overall message: near-term clinical readouts and regulatory interactions are the primary catalysts; the company believes its monoclonal approach offers a favorable tolerability profile versus reactogenic vaccines and has broader platform potential across infectious diseases.